Biotech Values

[buckiii2]

ILNS has Royalty Bearing Licensing Agreements with several
Big Pharma so if certain things happen in the future it will mean many millions of dollars in NEW revenue streams for ILNS. It will give ILNS revenue streams in the many millions of dollars.

Do people not know or are not aware of this?
Do people not care about this?
Do people not believe it?


It is all in the SEC filings: ( READ!!! )

http://www.sec.gov/Archives/edgar/data/1...

http://www.sec.gov/Archives/edgar/data/1...

http://www.sec.gov/Archives/edgar/data/1...

http://www.sec.gov/Archives/edgar/data/1...


"The Company has significant intellectual property assets, which include several patent families underlying the Company's internal programs, and a pivotal patent estate regarding passive Alzheimer's immunotherapy."

"The Company's ANTISENILIN® patent estate claims monoclonal antibodies that bind either end of amyloid beta but do not interact with the amyloid precursor protein from which amyloid beta is produced in the body. This high degree of specificity is an important safety feature, reducing the potential for adverse affects. Examples of monoclonal antibodies exhibiting this property are Bapineuzumab and Ponezumab, which are in Alzheimer's Phase 3 and Phase 2 clinical trials, respectively (http://clinicaltrials.gov/ct2/show/NCT00... http://clinicaltrials.gov/ct2/results?te...

Patents have been granted in Europe, Japan, China and elsewhere and in the United States. Intellect has granted royalty-bearing licenses to its ANTISENILIN® patent estate to several top tier global pharmaceutical companies developing monoclonal antibodies for Alzheimer's disease. For further information, see the Company's filings with the Securities and Exchange Commission." SEE ABOVE LINKS.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=122701&tid=1496&mid=1496&tof=1&frt=1.
.
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_I/threadview?m=tm&bn=122701&tid=1496&mid=1509&tof=1&frt=1